<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Bras Cir Cardiovasc</journal-id><journal-title-group><journal-title>Revista Brasileira de Cirurgia Cardiovascular : &#x000f3;rg&#x000e3;o oficial da Sociedade Brasileira de Cirurgia Cardiovascular</journal-title></journal-title-group><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25714213</article-id><article-id pub-id-type="pmc">4408822</article-id><article-id pub-id-type="doi">10.5935/1678-9741.20140078</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Nebivolol in preventing atrial fibrillation following coronary surgery in
patients over 60 years of age</article-title><trans-title-group xml:lang="pt"><trans-title>Nebivolol na preven&#x000e7;&#x000e3;o da fibrila&#x000e7;&#x000e3;o atrial ap&#x000f3;s a cirurgia coron&#x000e1;ria em
pacientes acima de 60 anos de idade</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>Erdil</surname><given-names>Nevzat</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff01">1</xref><xref ref-type="corresp" rid="c01"/></contrib><contrib contrib-type="author"><name><surname>Kaynak</surname><given-names>Murat</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>D&#x000f6;nmez</surname><given-names>K&#x000f6;ksal</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Disli</surname><given-names>Olcay Murat</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Battaloglu</surname><given-names>Bektas</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff01">1</xref></contrib><aff id="aff01"><label>1</label>Inonu University Turgut Ozal Medical Center, Malatya,
Turkey.</aff></contrib-group><author-notes><corresp id="c01">Correspondence address: Nevzat Erdil, Inonu University Turgut Ozal
Medical Center, Division of Cardiac Surgery, Malatya, Turkey, 44280. E-mail:
<email>nevzatkutay@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Oct-Dec</season><year>2014</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Oct-Dec</season><year>2014</year></pub-date><volume>29</volume><issue>4</issue><fpage>581</fpage><lpage>587</lpage><history><date date-type="received"><day>07</day><month>1</month><year>2014</year></date><date date-type="accepted"><day>08</day><month>6</month><year>2014</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited. </license-p></license></permissions><abstract><sec><title>Objective</title><p>Postoperative atrial fibrillation is a common complication after cardiac surgery,
with an incidence as high as 20-50%. Increased age is associated with a
significant increase in postoperative atrial fibrillation risk. This common
complication is associated with higher morbidity and mortality rates. The aim of
this study was to assess the efficacy of nebivolol in preventing atrial
fibrillation following coronary artery bypass surgery in patients over 60 years of
age.</p></sec><sec><title>Methods</title><p>In this prospective randomized study, 200 patients who were candidates for
elective coronary artery bypass surgery were divided into two groups. The first
group was administered with nebivolol and the second group was administered with
metoprolol. Treatment was initiated four days prior to surgery, and patients were
monitored for atrial fibrillation until discharge. Forty-one patients recieved 50
mg metoprolol succinate daily, which was initiated minimum 4 days before
surgery.</p></sec><sec><title>Results</title><p>Demographic data were similar in both groups. The incidence of postoperative
atrial fibrillation in both groups was similar, with no significant difference
being identified [n=20 (20%); n=18 (18%), <italic>P</italic>=0.718; respectively].
There were not any mortality at both groups during study. Inotropic agent
requirement at ICU was similar for both groups [n=12 (12%), n=18 (18%),
<italic>P</italic>=0.32].</p></sec><sec><title>Conclusion</title><p>We compared the effectiveness of nebivolol and metoprolol in decreasing the
incidence of postoperative atrial fibrillation, and determined that nebivolol was
as effective as metoprolol in preventing postoperative atrial fibrillation at
patients. Nebivolol may be the drug of choice due to its effects, especially after
elective coronary artery bypass surgery.</p></sec></abstract><trans-abstract xml:lang="pt"><sec><title>Objetivo</title><p>P&#x000f3;s-operat&#x000f3;rio fibrila&#x000e7;&#x000e3;o atrial &#x000e9; uma complica&#x000e7;&#x000e3;o comum ap&#x000f3;s a cirurgia card&#x000ed;aca,
com uma incid&#x000ea;ncia t&#x000e3;o elevada quanto 20-50%. O aumento da idade est&#x000e1; associado
com eleva&#x000e7;&#x000e3;o significativa no risco de p&#x000f3;s-operat&#x000f3;rio da fibrila&#x000e7;&#x000e3;o atrial. Esta
complica&#x000e7;&#x000e3;o comum &#x000e9; associada com taxas de morbidade e mortalidade. O objetivo
deste estudo foi avaliar a efic&#x000e1;cia do nebivolol na preven&#x000e7;&#x000e3;o da fibrila&#x000e7;&#x000e3;o atrial
ap&#x000f3;s cirurgia de revasculariza&#x000e7;&#x000e3;o do mioc&#x000e1;rdio de pacientes acima de 60 anos de
idade.</p></sec><sec><title>M&#x000e9;todos</title><p>Neste estudo prospectivo e randomizado, duzentos pacientes candidatos &#x000e0; cirurgia
de revasculariza&#x000e7;&#x000e3;o do mioc&#x000e1;rdio foram divididos em dois grupos. O primeiro grupo
foi administrado com nebivolol e o segundo grupo, com metoprolol. O tratamento foi
iniciado quatro dias antes da cirurgia, e os pacientes foram monitorados para
fibrila&#x000e7;&#x000e3;o atrial at&#x000e9; a alta. Quarenta e um pacientes receberam 50 mg de sucinato
de metoprolol di&#x000e1;rio, que foi iniciado, no m&#x000ed;nimo, 4 dias antes da cirurgia.</p></sec><sec><title>Resultados</title><p>Os dados demogr&#x000e1;ficos foram semelhantes nos dois grupos. A incid&#x000ea;ncia de
fibrila&#x000e7;&#x000e3;o atrial p&#x000f3;s-operat&#x000f3;ria em ambos os grupos foi semelhante, com nenhuma
diferen&#x000e7;a significativa sendo identificado [n=20 (20%); n=18 (18%),
<italic>P</italic>=0,718; respectivamente]. N&#x000e3;o houve mortalidade em ambos os
grupos durante o estudo. A necessidade de agente inotr&#x000f3;pico em UTI foi semelhante
nos dois grupos [n=12 pessoas (12%), n=18 (18%), <italic>P</italic>=0,32].</p></sec><sec><title>Conclus&#x000e3;o</title><p>N&#x000f3;s comparamos a efic&#x000e1;cia do nebivolol e metoprolol na diminui&#x000e7;&#x000e3;o da incid&#x000ea;ncia de
fibrila&#x000e7;&#x000e3;o atrial no p&#x000f3;s-operat&#x000f3;rio, e verificamos que nebivolol foi t&#x000e3;o eficaz
como metoprolol na preven&#x000e7;&#x000e3;o de fibrila&#x000e7;&#x000e3;o atrial no p&#x000f3;s-operat&#x000f3;rio em pacientes.
Nebivolol pode ser a droga de escolha devido aos seus efeitos, especialmente
depois da cirurgia revasculariza&#x000e7;&#x000e3;o do mioc&#x000e1;rdio.</p></sec></trans-abstract><kwd-group><kwd>Coronary Artery Bypass</kwd><kwd>Atrial Fibrillation</kwd><kwd>Anti-Arrhythmia Agents</kwd><kwd>Drug Therapy</kwd></kwd-group></article-meta></front><body><table-wrap id="t01" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr><th colspan="2" align="left" rowspan="1">Abbreviations, acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">AF</td><td rowspan="1" colspan="1">Atrial fibrillation</td></tr><tr><td rowspan="1" colspan="1">CPB</td><td rowspan="1" colspan="1">Cardiopulmonary bypass</td></tr><tr><td rowspan="1" colspan="1">DVT</td><td rowspan="1" colspan="1">Deep vein thrombosis</td></tr><tr><td rowspan="1" colspan="1">ECG</td><td rowspan="1" colspan="1">Electrocardiogram</td></tr><tr><td rowspan="1" colspan="1">EuroSCORE</td><td rowspan="1" colspan="1">(European) System For Cardiac Operative Risk</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;</td><td rowspan="1" colspan="1">Evaluation Score</td></tr><tr><td rowspan="1" colspan="1">ICU</td><td rowspan="1" colspan="1">Intensive care unit</td></tr><tr><td rowspan="1" colspan="1">LMCA</td><td rowspan="1" colspan="1">Left main coronary artery</td></tr><tr><td rowspan="1" colspan="1">MI</td><td rowspan="1" colspan="1">Myocardial infarction</td></tr><tr><td rowspan="1" colspan="1">POAF</td><td rowspan="1" colspan="1">Postoperative atrial fibrillation</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Postoperative atrial fibrillation (POAF) is a commonly observed complication following
cardiac surgery, with an incidence as high as 20-50% depending on the accepted
definition of POAF and the methods used for detection<sup>[<xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>]</sup>. Increasing age
in patients undergoing cardiac surgery is associated with a significant increase in POAF
risk<sup>[<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref>]</sup>. This common complication contributes to higher morbidity and
mortality rates among patients. Major outcomes associated with POAF include an increased
incidence of stroke, longer hospitalization, increased hospital costs, and higher early
and late mortality rates<sup>[<xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref>]</sup>.</p><p>Prophylactic treatment is recommended due to the high incidence of POAF, especially if
risk factors are present. Effective preventive and treatment strategies are important
for reducing the undesirable effects of this complication. It has been previously
demonstrated in several studies that beta-blockers are effective agents for preventing
POAF. Beta-blockers have also been recommended for POAF prophylaxis in several
meta-analyses<sup>[<xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref>]</sup>. Nebivolol is a selective beta-1 adrenergic receptor
antagonist that differs from conventional beta-blockers in its ability to induce nitric
oxide synthesis in the human endothelium. Tepliakov et al.<sup>[<xref rid="r08" ref-type="bibr">8</xref>]</sup> showed that nebivolol administration (1.25-5.0 mg/day)
increased exercise tolerance, improved life quality, reduced IR index by 11.9%, and
reduced triglyceride levels by 5.3% (which in turn lowered the risk of effects
associated with diabetic atherogenic dyslipidemia).</p><p>In this prospective randomized study, we investigated the effectiveness of nebivolol and
metoprolol in decreasing the incidence of POAF. Patients in this study were selected
among individuals above 60 years of age, as age is a major risk factor for POAF. There
are no other studies in the literature regarding the effects of nebivolol in preventing
POAF.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Following the approval of the Medical Faculty's Ethics Committee (Reference Number:
2009/145), and after written informed consents were obtained from the patients; 200
patients over 60 years of age with coronary artery disease, who had been admitted to our
clinic for elective coronary artery bypass grafting surgery, were included into our
study.</p><p>The study was performed according to a randomized, prospective, parallel-group, active
controlled, open-label, single-blind study design. The patients were randomized into two
groups, and the study procedures were carried out for a period of 4 days. All included
patients were from an inpatient setting. Study subjects were randomly allocated into the
NEB and MET treatment groups at the beginning of the study by using a random number
generated by SAS.</p><p>The patients were not stratified according to race and sex during the randomization
process, which led to an unequal distribution of males and females between the two
groups. At the beginning of the study 100 subjects were recruited in each group. Due to
the withdrawal of consent, lost to follow-up and missing values of some outcome
variables, the final sample size was 100 in the NEB group and 100 in the MET group.</p><p>Group 1 was the nebivolol group, consisting of 100 patients (27 women and 73 men, mean
age 67.2&#x000b1;7.6), while Group 2 was the metoprolol group, also consisting of 100 patients
(34 women and 67 men, mean age 68.4&#x000b1;5.8). Patients who had previous beta-blocker or
antiarrhythmic treatment, previous atrial fibrillation (AF), heart failure (ejection
fraction &#x0003c; 35%), sick sinus syndrome, atrioventricular block, permanent pacemaker,
valvular surgery, peripheral vascular disease, hyperthyroidism, and emergency surgery
were excluded from the study. In both groups, drugs use was started 4 days prior to
surgery<sup>[<xref rid="r09" ref-type="bibr">9</xref>]</sup>.</p><p>Metoprolol was administered once daily at a dose of 50 mg, while nebivolol was
administered once daily at a dose of 5 mg. Drug use was continued after extubation
during the postoperative period. Dosages were adjusted according to the hemodynamic
responses of the patients after coronary surgery. None of the patients withdrew from
study due to the side effects of the drugs.</p><p>Data was collected at the time of hospitalization, during the first postoperative day,
and at the time of discharge. The primary end point of the study was new-onset AF until
discharge. None of the patients in both groups presented serious bradycardia or
hypotension. Atrial fibrillation was diagnosed when 12-lead ECG showed rapid
oscillations or fibrillatory <italic>P</italic> waves that varied in size, shape, and
timing, and which were associated with irregular QRS complexes.</p><p>In this study, POAF was defined as AF of any duration during the postoperative period,
with the AF diagnosis being based on the physician's assessments. All Holter and ECG
data were evaluated by two blinded cardiologists, and AF diagnosis was confirmed with
the observation of (i) absent P wave prior to QRS complex, and (ii) irregular
ventricular rhythm that continued for more than 5 minutes. In the event that POAF was
identified, no further evaluations were performed, and the patient was started on an
administration of amiodarone at a 150 mg bolus dose, followed by administration at 15
mg/kg/24 h infusion. After sinus rythm was achieved, the patient's treatment was
continued with oral amiodarone administration for a period of 30 days, with a 800 mg/day
dose being administered during week 1, a 600 mg/day dose during week 2, a 400 mg/day
dose during week 3, and a 200 mg/day dose during week 4.</p><p>ECG and 12-lead ECG were needed to confirm the 12-lead ECG findings. Patients who
developed AF were treated with a standard protocol of anticoagulation and amiodarone.
None of patients who developed AF required electrical cardioversion. All of the patients
were discharged from the hospital with a sinus rhythm.</p><sec><title>Statistical analysis</title><p>Data were analyzed using the Statistical Package for Social Sciences 16.0 (SPSS 16.0)
for Windows (SPSS Inc., Chicago, IL). Data for patient characteristics and outcomes
were expressed either as percentage of total or as mean&#x000b1;SD. The independent samples
t-test was used for normally distributed continuous variables (expressed as mean&#x000b1;SD),
while the Pearson chi-square, Yates' corrected chi-square and Fisher's exact tests
were used for categorical variables, where applicable. The Mann Whitney U test was
used for continuous variables such as age, BMI and EuroSCORE, which were not normally
distributed. The results were assessed within 95% confidence, and a value of
<italic>P</italic> &#x0003c;0.05 was considered as statistically significant.</p></sec><sec><title>Surgical Procedure</title><p>Patients were placed under general anesthesia, and conventional median sternotomy was
performed. Each patient underwent on-pump coronary artery bypass grafting surgery,
and cardiopulmonary bypass was established by cannulating the ascending aorta and
right atrium. Heparin (3 mg/kg) was administered for anticoagulation. Activated
clotting time was maintained for longer than 450 seconds, and a roller pump and
non-pulsatile flow (2.4 L/m<sup>2</sup>/min) were used.</p><p>The body was cooled to a core temperature between 32&#x000ba;C and 34&#x000ba;C when performing
distal anastomosis, and the body was rewarmed to 36&#x000ba;C before weaning from
cardiopulmonary bypass. Cold blood cardioplegia was delivered intermittently via
antegrade and retrograde routes throughout the procedure. A final dose of "hot-shot"
cardioplegia was delivered intermittently via antegrade and retrograde routes
throughout the procedure. A final dose of "hot-shot" cardioplegia was administered
immediately before the aorta was unclamped. An epicardial temporary pacemaker lead
(FLEXON 3-0 temporary cardiac pacing lead, Syneture, Covidien, US) was placed on the
right ventricle. Details of the surgical techniques used for complete
revascularization solely by means of arterial grafts have been previously
described<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>The same protocol was applied for each case in which radial artery was used.
Radial-artery harvesting was carried out simultaneously with left internal thoracic
artery harvesting. Saphenous veins were harvested using conventional methods. The
choice of graft material was left to the surgeon, but certain protocols were
followed. Left internal thoracic artery was generally used as a graft for the left
anterior descending artery; radial artery and saphenous vein graft conduits were used
mainly to bypass vessels other than the left anterior descending artery; and only
radial artery conduits were used to bypass vessels other than the left anterior
descending artery in case they exhibited more than 70% stenosis.</p></sec><sec><title>Outcome parameters</title><p>A prospective study was performed for the relevant pre-operative, intraoperative and
postoperative data of the study group. The specific pre- and intraoperative data
obtained from each patient included the following: age and gender, history of
hypertension, diabetes, smoking, obesity, hyperlipidemia, body surface area and body
mass index (BMI), history of myocardial infarction (MI), the presence of unstable
angina, prior percutaneous transluminal coronary angioplasty, the presence of carotid
artery disease, left ventricular ejection fraction, the presence of left main
coronary artery (LMCA) disease, additive EuroSCORE and the extent of coronary
disease.</p><p>The postoperative data that was collected included the number of grafts per
operation, the graft types that were used (i.e., left internal mammary artery, radial
artery or saphenous vein grafts), the cardiopulmonary bypass time, the aortic
cross-clamp time, the mechanical ventilation time, the requirement for inotropic or
intra-aortic balloon pump support, presence of infection, re-exploration for bleeding
or cardiac tamponade, the duration of stay in the intensive care unit (ICU), overall
duration of hospital stay, and hospital mortality (defined as death in the first 30
days after coronary artery bypass grafting surgery). We further employed data
regarding study design, baseline patient data, administered treatment and POAF
incidence by entering them to an Excel spreadsheet that was standardized. POAF
incidence was considered as the study's primary outcome.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Two hundred patients (100 patients per group) were included into this study. The
pre-operative demographic characteristics of the patients are summarized in <xref ref-type="table" rid="t02">Table 1</xref> and <xref ref-type="table" rid="t03">Table
2</xref>. The mean age of the patients was 67.2&#x000b1;7.6 years in Group 1, and 68.4&#x000b1;5.8
years in Group 2.</p><table-wrap id="t02" orientation="portrait" position="float"><label>Table 1</label><caption><p>Preoperative demographic data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-Value</th></tr><tr><th rowspan="1" colspan="1">Nebivolol</th><th rowspan="1" colspan="1">Metoprolol</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Mean Age</td><td align="center" rowspan="1" colspan="1">67.2 &#x000b1; 7.6</td><td align="center" rowspan="1" colspan="1">68.4 &#x000b1; 5.8</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">Gender (Female)</td><td align="center" rowspan="1" colspan="1">27 (27%)</td><td align="center" rowspan="1" colspan="1">34 (34%)</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td rowspan="1" colspan="1">Previous MI</td><td align="center" rowspan="1" colspan="1">43 (43%)</td><td align="center" rowspan="1" colspan="1">46 (46%)</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td rowspan="1" colspan="1">Diabetes Mellitus</td><td align="center" rowspan="1" colspan="1">31 (31%)</td><td align="center" rowspan="1" colspan="1">28 (28%)</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">25 (25%)</td><td align="center" rowspan="1" colspan="1">33 (33%)</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">52 (52%)</td><td align="center" rowspan="1" colspan="1">45 (45%)</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td rowspan="1" colspan="1">COPD</td><td align="center" rowspan="1" colspan="1">14 (14%)</td><td align="center" rowspan="1" colspan="1">8 (8%)</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td rowspan="1" colspan="1">Hypercholesterolemia</td><td align="center" rowspan="1" colspan="1">58 (58%)</td><td align="center" rowspan="1" colspan="1">66 (66%)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">Obesity</td><td align="center" rowspan="1" colspan="1">25 (25%)</td><td align="center" rowspan="1" colspan="1">24 (24%)</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td rowspan="1" colspan="1">Renal Dysfunction</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">2 (2%)</td><td align="center" rowspan="1" colspan="1">0.49</td></tr><tr><td rowspan="1" colspan="1">BMI</td><td align="center" rowspan="1" colspan="1">26.9&#x000b1;4.1</td><td align="center" rowspan="1" colspan="1">26.6&#x000b1;4.4</td><td align="center" rowspan="1" colspan="1">0.574</td></tr><tr><td rowspan="1" colspan="1">EuroSCORE</td><td align="center" rowspan="1" colspan="1">3.55&#x000b1;2.02</td><td align="center" rowspan="1" colspan="1">4.1&#x000b1;2.28</td><td align="center" rowspan="1" colspan="1">0.072</td></tr><tr><td rowspan="1" colspan="1">BSA</td><td align="center" rowspan="1" colspan="1">1.78&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">1.75&#x000b1;0.16</td><td align="center" rowspan="1" colspan="1">0.274</td></tr></tbody></table><table-wrap-foot><fn><p>COPD=Chronic Obstructive Pulmonary Disease; BMI=Body Mass Index; BSA=Body
Surface Area</p></fn></table-wrap-foot></table-wrap><table-wrap id="t03" orientation="portrait" position="float"><label>Table 2</label><caption><p>Preoperative demographic data (cardiac).</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-Value</th></tr><tr><th rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Nebivolol</th><th align="center" rowspan="1" colspan="1">Metoprolol</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Number of Diseased Vessels</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">One Vessel</td><td align="center" rowspan="1" colspan="1">8 (8%)</td><td align="center" rowspan="1" colspan="1">8 (8%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Two Vessel</td><td rowspan="1" colspan="1">45 (47%)</td><td rowspan="1" colspan="1">50 (50%)</td><td rowspan="1" colspan="1">0.479</td></tr><tr><td rowspan="1" colspan="1">Three Vessel</td><td align="center" rowspan="1" colspan="1">47 (47%)</td><td align="center" rowspan="1" colspan="1">42 (42%)</td><td align="center" rowspan="1" colspan="1">0.477</td></tr><tr><td rowspan="1" colspan="1">LMCA disease</td><td align="center" rowspan="1" colspan="1">6 (6%)</td><td align="center" rowspan="1" colspan="1">8 (8%)</td><td align="center" rowspan="1" colspan="1">0.78</td></tr><tr><td rowspan="1" colspan="1">Right Coronary Disease</td><td align="center" rowspan="1" colspan="1">66 (66%)</td><td align="center" rowspan="1" colspan="1">71 (71%)</td><td align="center" rowspan="1" colspan="1">0.44</td></tr><tr><td rowspan="1" colspan="1">Carotid artery disease</td><td align="center" rowspan="1" colspan="1">10 (10%)</td><td align="center" rowspan="1" colspan="1">5 (5%)</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td rowspan="1" colspan="1">Previous PTCA</td><td align="center" rowspan="1" colspan="1">13 (13%)</td><td align="center" rowspan="1" colspan="1">22 (22%)</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td rowspan="1" colspan="1">Ejection fraction</td><td align="center" rowspan="1" colspan="1">50.2 &#x000b1; 8.1</td><td align="center" rowspan="1" colspan="1">50.9 &#x000b1; 8.6</td><td align="center" rowspan="1" colspan="1">0.533</td></tr><tr><td rowspan="1" colspan="1">New MI</td><td align="center" rowspan="1" colspan="1">6 (6%)</td><td align="center" rowspan="1" colspan="1">17 (17%)</td><td align="center" rowspan="1" colspan="1">0.027</td></tr><tr><td rowspan="1" colspan="1">Unstable Angina</td><td align="center" rowspan="1" colspan="1">13 (13%)</td><td align="center" rowspan="1" colspan="1">21 (21%)</td><td align="center" rowspan="1" colspan="1">0.19</td></tr></tbody></table><table-wrap-foot><fn><p>LMCA=Left Main coronary Artery Disease; PTCA=Percutaneous Transluminal Coronary
Angioplasty; MI=Myocardial Infarction</p></fn></table-wrap-foot></table-wrap><p>There were no significant differences between the groups with respect to gender
distribution; the prevalence of chronic obstructive pulmonary disease; the frequency of
previous percutaneous transluminal coronary angioplasty; the prevalence of hypertension,
obesity (body mass index, &#x02265; 30 kg/m<sup>2</sup>), hyperlipidemia, smoking, diabetes
mellitus, unstable angina, or LMCA disease; the ratio of patients with a history of MI;
or the ratio of patients with carotid artery disease. There were also no statistical
differences between the groups with respect to the mean number of diseased vessels, the
mean left ventricular ejection fraction, or the EuroSCORE.</p><p>Intraoperative and postoperative data that were collected included the number of grafts
per operation, the types of grafts used (for example, left internal thoracic artery,
radial artery, and venous grafts), the cardiopulmonary bypass (CPB) time, and the aortic
cross-clamp time. Data collected regarding the postoperative outcomes included the
mechanical ventilation time; the requirement for inotropic or intra-aortic balloon pump
support; the development of atrial fibrillation or infective complications; the
re-exploration for bleeding or cardiac tamponade; and the occurrence of major pleural
effusions, superficial or deep-wound infections, and deep vein thrombosis (DVT).</p><p>With regards to inotrope usage, hypoxemia and low cardiac output, no statistically
significant differences were observed between the two groups. Similarly, there was also
no statistically significant difference between Group 1 and Group 2 in any of the types
of data described above (<xref ref-type="table" rid="t04">Table 3</xref>).</p><table-wrap id="t04" orientation="portrait" position="float"><label>Table 3</label><caption><p>Operative data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr><th rowspan="1" colspan="1">Nebivolol</th><th rowspan="1" colspan="1">Metoprolol</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">N</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">Preoperative Mortality</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1">Complete arterial</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td rowspan="1" colspan="1">revascularization</td><td align="center" rowspan="1" colspan="1">3 (3%)</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td rowspan="1" colspan="1">LIMA usage</td><td align="center" rowspan="1" colspan="1">96 (96%)</td><td align="center" rowspan="1" colspan="1">95 (95%)</td><td align="center" rowspan="1" colspan="1">0.733</td></tr><tr><td rowspan="1" colspan="1">Radial Artery usage</td><td align="center" rowspan="1" colspan="1">7 (7%)</td><td align="center" rowspan="1" colspan="1">4 (4%)</td><td align="center" rowspan="1" colspan="1">0.352</td></tr><tr><td rowspan="1" colspan="1">Mean distal bypass number</td><td align="center" rowspan="1" colspan="1">2.40 &#x000b1; 0.67</td><td align="center" rowspan="1" colspan="1">2.38 &#x000b1; 0.69</td><td align="center" rowspan="1" colspan="1">0.835</td></tr><tr><td rowspan="1" colspan="1">Cross-clamp time (min)</td><td align="center" rowspan="1" colspan="1">64.6 &#x000b1; 16.5</td><td align="center" rowspan="1" colspan="1">62.6 &#x000b1; 15.7</td><td align="center" rowspan="1" colspan="1">0.423</td></tr><tr><td rowspan="1" colspan="1">Perfusion time (min)</td><td align="center" rowspan="1" colspan="1">74.7 &#x000b1; 17.6</td><td align="center" rowspan="1" colspan="1">74.2 &#x000b1; 16.9</td><td align="center" rowspan="1" colspan="1">0.838</td></tr></tbody></table><table-wrap-foot><fn><p>LIMA=Left Internal Mammarian artery</p></fn></table-wrap-foot></table-wrap><p>Group I and Group II had similar durations of stay in the intensive care unit (2.6&#x000b1;0.7
vs. 2.5&#x000b1;0.9 days, respectively; <italic>P</italic> =0.559), durations of overall
hospital stay (7.1&#x000b1;1.4 vs. 7.4&#x000b1;2.2 days, respectively; <italic>P</italic> =0.388) and
ventilation times (7.3&#x000b1;2.5 vs. 7.2&#x000b1;2.9 hours, respectively; <italic>P</italic> =0.794),
with no significant differences being identified between the two groups. In addition, no
perioperative deaths occurred in any of these two groups.</p><p>There was no significant difference in the incidence of POAF between Group I and Group
II (20% vs. 18%, respectively; <italic>P</italic> =0.718). The incidence of inotropic
agent requirement at ICU were also similar in both groups (12% in Group I vs. 18% in
Group II, <italic>P</italic> =0.32) (<xref ref-type="table" rid="t05">Table
4</xref>).</p><table-wrap id="t05" orientation="portrait" position="float"><label>Table 4</label><caption><p>Postoperative data.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Group 1</th><th align="center" rowspan="1" colspan="1">Group 2</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr><tr><th rowspan="1" colspan="1">Nebivolol</th><th rowspan="1" colspan="1">Metoprolol</th><th rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Requirement for Inotropes</td><td align="center" rowspan="1" colspan="1">11 (11%)</td><td align="center" rowspan="1" colspan="1">22 (22%)</td><td align="center" rowspan="1" colspan="1">0.057</td></tr><tr><td rowspan="1" colspan="1">IABP</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Ventilation time (hours)</td><td align="center" rowspan="1" colspan="1">7.3 &#x000b1; 2.5</td><td align="center" rowspan="1" colspan="1">7.2 &#x000b1; 2.9</td><td align="center" rowspan="1" colspan="1">0.794</td></tr><tr><td rowspan="1" colspan="1">ICU stay (days)</td><td align="center" rowspan="1" colspan="1">2.6 &#x000b1; 0.7</td><td align="center" rowspan="1" colspan="1">2.5 &#x000b1; 0.9</td><td align="center" rowspan="1" colspan="1">0.559</td></tr><tr><td rowspan="1" colspan="1">Surgical site infection</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Re-exploration for bleeding or tamponade</td><td align="center" rowspan="1" colspan="1">3 (3%)</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td rowspan="1" colspan="1">Pleural effusion</td><td align="center" rowspan="1" colspan="1">3 (3%)</td><td align="center" rowspan="1" colspan="1">0 (0%)</td><td align="center" rowspan="1" colspan="1">0.24</td></tr><tr><td rowspan="1" colspan="1">DVT</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">1 (1%)</td><td align="center" rowspan="1" colspan="1">1.000</td></tr><tr><td rowspan="1" colspan="1">Atrial Fibrillation</td><td align="center" rowspan="1" colspan="1">20 (20%)</td><td align="center" rowspan="1" colspan="1">18 (18%)</td><td align="center" rowspan="1" colspan="1">0.718</td></tr><tr><td rowspan="1" colspan="1">Inotrope requirement in</td><td align="center" rowspan="1" colspan="1">12 (12%)</td><td align="center" rowspan="1" colspan="1">18 (18%)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td colspan="4" rowspan="1">ICU</td></tr><tr><td rowspan="1" colspan="1">Hospital Stay (days)</td><td align="center" rowspan="1" colspan="1">7.1 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">7.4 &#x000b1; 2.2</td><td align="center" rowspan="1" colspan="1">0.388</td></tr></tbody></table><table-wrap-foot><fn><p>IABP=Intra-aortic Balloon Pump; ICU=Intensive Care Unit; DVT=Deep Vein
Thrombosis</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The aim of this study was to investigate the effectiveness of nebivolol in the
prophylaxis of postoperative atrial fibrillation (POAF) by comparing it with metoprolol,
a medication whose effectiveness against atrial fibrillation is well-documented. Based
on the study results, we identified no significant difference between nebivolol and
metoprolol with regards to the effectiveness of POAF prophylaxis. POAF is observed in
nearly 30% of patients who undergo isolated coronary artery bypass (CABG) surgery. This
ratio increases to nearly 40% if replacement or repair of valves is performed during
surgery, and to 50% in case combined procedures are performed. Considering that the age
average of populations undergoing cardiac surgery is gradually increasing, and that the
incidence of POAF is positively correlated with age, it is likely that these percentages
will increase in the future.</p><p>In most cases, POAF develops between the 2<sup>nd</sup> and 4<sup>th</sup> days that
immediately follow surgery, with the highest incidence being observed on the
2<sup>nd</sup> day. The onset of POAF occurs before the 4<sup>th</sup> postoperative
day in 70% of cases, and before the 6<sup>th</sup> postoperative day in 94% of
cases<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>POAF often manifests itself as a transient condition that is tolerated by most patients.
However, POAF also has the potential to cause serious complications or even be fatal in
certain patients - especially older patients and patients with certain ventricular
dysfunctions<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> and
mortality<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. POAF was
previously described as a potential cause of significant morbidity<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup> that can lead to further postoperative
complications such as thromboembolism<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, hemodynamic problems<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>, ventricular dysrhythmias<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>, and even to iatrogenetic effects due to inappropriate diagnosis
and treatment of POAF.</p><p>Moreover, POAF is known to increase nearly three times the incidence of perioperative
stroke<sup>[<xref rid="r13" ref-type="bibr">13</xref>-<xref rid="r17" ref-type="bibr">17</xref>]</sup>. In a study conducted by Almassi et al. on 3855 cardiac
surgery patients<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, it was observed
that POAF led to a nearly two-fold increase in the hospital mortality and the 6-month
mortality of patients. Increasing age is the most significant contributing factor to the
risk of POAF<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Matthew et
al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> determined in a recently
conducted study that the incidence of POAF increased by nearly 75% for every decade of
age, and that all patients above the age of 70 were at a high risk of POAF.</p><p>Other factors that also increase the risk of POAF include previous episodes of AF, lower
left ventricular ejection fraction, left atrial enlargement, valvular heart surgery,
chronic obstructive pulmonary disease, chronic renal failure, diabetes mellitus, and
rheumatic heart diseases<sup>[<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Recent students have also suggested that obesity may be associated
with a higher incidence of POAF in both patients with and without previous cardiac
surgeries<sup>[<xref rid="r19" ref-type="bibr">19</xref>,<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>A variety of factors appear to be involved in the etiology of POAF, although the
mechanistic relationship between these factors and POAF development has not yet been
clearly identified. Several mechanisms that are potentially involved in POAF
pathogenesis include pericardial inflammation, excessive catecholamine production,
postoperative autonomic imbalance, and interstitial fluid mobilization. These factors
may adversely affect atrial refractoriness and slow atrial conduction. The multiple
re-entry wavelets caused by the dispersion of atrial refractoriness appear to be the
underlying mechanism for the development of POAF<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>In a meta-analysis performed recently by Crystal et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, it was observed that, within the scope of 28 trials
conducted with 4074 subjects, beta-blocker drugs demonstrated the highest magnitude of
effect with an odds ratio (OR) of 0.3, and a 95% confidence interval (CI) of 02.26 to
0.49. In the meta-analysis of Burgess et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>, the authors reported that the use of beta-blocker drugs lead to
a reduction in the incidence of POAF.</p><p>According to the American College of Cardiology/American Heart Association and the
European Society of Cardiology Guidelines for AF; pre-operative or early postoperative
administration of beta-blockers for preventing AF after coronary artery bypass grafting
surgery in patients without contraindications is a class-1 indication, with an evidence
level of A<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.</p><p>Nebivolol is a third generation selective beta-1 adrenergic receptor antagonist that
differs from conventional beta-blockers in its ability to induce nitric oxide synthesis
in the endothelium<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. The
endothelium produces nitric oxide, which is a well-known vasodilator. Nebivolol has a
high beta-1 adrenergic receptor selectivity, and can be used safely in patients with
reduced cardiac functions.</p><p>There are numerous studies discussing other properties of Nebivolol; however, based on
our review of the literature, we believe that our study was the first to investigate the
prophylactic use of nebivolol for POAF after coronary artery bypass surgery.</p><p>Metoprolol is an important drug that was approved by the FDA in 1978. We chose
metoprolol for comparison with nebivolol due to its safety and common use. Metoprolol
has been used for the prevention and treatment of postoperative AF for decades. Thus, in
this study we aimed to investigate the effectiveness of nebivolol in the prophylaxis of
POAF by comparing it with metoprolol</p><p>Radial arterial graft vasospasm is one of the most problematic complications following
cardiac surgery. As mentioned before, nebivolol possesses a potent vasodilator effect on
radial artery graft, and can increase the lumen diameter and protect the
graft<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>.</p><p>Furthermore, nebivolol is also known to improve sleep parameters, which contributes
positively to the patients' life quality<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. Disturbance of normal sleep, in particular, may cause tiredness
and lead to depression. This is most important for postoperative patients, who are
emotionally vulnerable after surgery. Owing to its electrophysiological properties, and
in a manner similar to other beta-blockers; nebivolol has the effect of increasing the
ventricular fibrillation threshold.</p><p>This effect allows nebivolol to reduce ventricular arrhythmia or drug-induced
cardiomyopathy in various animal models. Nebivolol is also known to reduce the QT
dispersions, which are associated with the risk of developing arrhythmias, and P-wave
dispersions, which are associated with the risk of developing atrial
fibrillation<sup>[<xref rid="r28" ref-type="bibr">28</xref>]</sup>. We believe
that the results we obtained for nebivolol in our study - which were not significantly
different than those for metoprolol - were ultimately the result of the effects and
mechanisms described above.</p><p>Previous experiments on ischemia and reperfusion injury<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup> have also demonstrated the preventive and protective
effects of nebivolol. In addition, it was shown that the administration of nebivolol in
humans increased tolerance during exercise (in comparison to atenolol), as well as the
time required for the onset of angina<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>. Nebivolol was also demonstrated to have a consistent effect in
increasing coronary flow among individuals with ischemic and nonischemic heart diseases,
which is believed to engender a decrease in the ischemic threshold of these
individuals<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>.</p><p>We believe that these effects that counter the damages associated with ischemia and
ischemia-reperfusion will also allow nebivolol to be effective in the prevention and
treatment of POAF. For ethical reasons, and also due to the relatively low number of
patients in our study groups, we did not to include into the study design a control
group without beta-blocker treatment. Unlike metoprolol, nebivolol does not have an IV
form, which also represents a disadvantage.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Metoprolol is a well-known and commonly preferred drug for the prevention of POAF. In
this study, Nebivolol was determined to be as effective as metoprolol. Thus, it is
possible to use nebivolol effectively for prophylaxis of POAF. Moreover, nebivolol's
characteristic properties may also result in additional benefits for elderly patients.
Due to the limitations of this study; well-planned prospective and randomized studies
with larger groups that evaluate other properties and features of nebivolol will be
necessary to gain further information. The contribution of such studies on the body of
knowledge regarding nebivolol's effects will be significant.</p><table-wrap id="t06" orientation="portrait" position="float"><table frame="box" rules="groups"><thead><tr align="left" valign="top"><th colspan="2" rowspan="1">Authors&#x02019; roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">NE</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical analysis, final
approval of manuscript</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MK</td><td rowspan="1" colspan="1">Final approval of manuscript, conception and study design, conduct of
operations, and/or experiments</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">KD</td><td rowspan="1" colspan="1">Study design, conduct of operations, and/or experiments</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">OMD</td><td rowspan="1" colspan="1">Analysis and/or interpretation of data, statistical analysis, final
approval of the manuscript, conception and study design, conduct of
operations, and/or experiments</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BB</td><td rowspan="1" colspan="1">Conception and design of the study</td></tr></tbody></table></table-wrap></sec></body><back><ref-list><title>REFERENCES</title><ref id="r01"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creswell</surname><given-names>LL</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>Rosenbloom</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>JL</given-names></name></person-group><article-title>Hazards of postoperative atrial arrhythmias</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>56</volume><issue>3</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">8379728</pub-id></element-citation></ref><ref id="r02"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>TC</given-names></name><name><surname>Reimold</surname><given-names>SC</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Antman</surname><given-names>EM</given-names></name></person-group><article-title>Prevention of supraventricular arrhythmias after coronary artery
bypass surgery: A meta-analysis of randomized control trials</article-title><source>Circulation</source><year>1991</year><volume>84</volume><issue>5 Suppl</issue><fpage>III236</fpage><lpage>III244</lpage><pub-id pub-id-type="pmid">1682069</pub-id></element-citation></ref><ref id="r03"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nisanoglu</surname><given-names>V</given-names></name><name><surname>Erdil</surname><given-names>N</given-names></name><name><surname>Aldemir</surname><given-names>M</given-names></name><name><surname>Ozgur</surname><given-names>B</given-names></name><name><surname>Berat Cihan</surname><given-names>H</given-names></name><name><surname>Yologlu</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Atrial fibrillation after coronary artery bypass grafting in elderly
patients: incidence and risk factor analysis</article-title><source>Thorac Cardiovasc Surg</source><year>2007</year><volume>55</volume><issue>1</issue><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">17285471</pub-id></element-citation></ref><ref id="r04"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aranki</surname><given-names>SF</given-names></name><name><surname>Shaw</surname><given-names>DP</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Rizzo</surname><given-names>RJ</given-names></name><name><surname>Couper</surname><given-names>GS</given-names></name><name><surname>VanderVliet</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Predictors of atrial fibrillation after coronary artery surgery.
Current trends and impact on hospital resources</article-title><source>Circulation</source><year>1996</year><volume>94</volume><issue>3</issue><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">8759081</pub-id></element-citation></ref><ref id="r05"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Savino</surname><given-names>JS</given-names></name><name><surname>Friedman</surname><given-names>AS</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Mangano</surname><given-names>DT</given-names></name><etal>et al</etal></person-group><article-title>Atrial fibrillation following coronary artery bypass graft surgery:
predictors, outcomes, and resource utilization. Multicenter Study of Perioperative
Ischemia Research Group</article-title><source>JAMA</source><year>1996</year><volume>276</volume><issue>4</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">8656542</pub-id></element-citation></ref><ref id="r06"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal>et al</etal></person-group><article-title>Meta-analysis of amiodarone versus &#x003b2;-blocker as a prophylactic therapy
against atrial fibrillation following cardiac surgery</article-title><source>Intern Med J</source><year>2012</year><volume>42</volume><issue>10</issue><fpage>1078</fpage><lpage>1087</lpage><pub-id pub-id-type="pmid">22646992</pub-id></element-citation></ref><ref id="r07"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>J</given-names></name><name><surname>Pezzullo</surname><given-names>J</given-names></name><name><surname>Choucair</surname><given-names>W</given-names></name><name><surname>Southard</surname><given-names>J</given-names></name><name><surname>Kokkinos</surname><given-names>P</given-names></name><name><surname>Karasik</surname><given-names>P</given-names></name><etal>et al</etal></person-group><article-title>Meta-analysis of antiarrhythmic therapy in the prevention of
postoperative atrial fibrillation and the effect on hospital length of stay,
costs, cerebrovascular accidents, and mortality in patients undergoing cardiac
surgery</article-title><source>Am J Cardiol</source><year>2003</year><volume>91</volume><issue>9</issue><fpage>1137</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">12714166</pub-id></element-citation></ref><ref id="r08"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tepliakov</surname><given-names>AT</given-names></name><name><surname>Kuznetsova</surname><given-names>AV</given-names></name><name><surname>Lukinov</surname><given-names>AV</given-names></name><name><surname>Levshin</surname><given-names>AV</given-names></name></person-group><article-title>Effects of a superselective beta1-adrenoblocker nebivolol on the
course of coronary heart disease and insulin resistance in patients with diabetes
mellitus type 2 after coronary artery bypass grafting</article-title><source>Ter Arkh</source><year>2007</year><volume>79</volume><issue>12</issue><fpage>38</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">18220029</pub-id></element-citation></ref><ref id="r09"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imren</surname><given-names>Y</given-names></name><name><surname>Benson</surname><given-names>AA</given-names></name><name><surname>Zor</surname><given-names>H</given-names></name><name><surname>Tasoglu</surname><given-names>I</given-names></name><name><surname>Ereren</surname><given-names>E</given-names></name><name><surname>Sinci</surname><given-names>V</given-names></name><etal>et al</etal></person-group><article-title>Preoperative beta-blocker use reduces atrial fibrillation in off-pump
coronary bypass surgery</article-title><source>ANZ J Surg</source><year>2007</year><volume>77</volume><issue>6</issue><fpage>429</fpage><lpage>432</lpage><pub-id pub-id-type="pmid">17501880</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nisanoglu</surname><given-names>V</given-names></name><name><surname>Battaloglu</surname><given-names>B</given-names></name><name><surname>Erdil</surname><given-names>N</given-names></name><name><surname>Ozgur</surname><given-names>B</given-names></name><name><surname>Aldemir</surname><given-names>M</given-names></name><name><surname>Cihan</surname><given-names>HB</given-names></name></person-group><article-title>Complete myocardial revascularization using arterial grafts only in
patients with unstable angina: impact on early outcome</article-title><source>Thorac Cardiovasc Surg</source><year>2007</year><volume>55</volume><issue>1</issue><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">17285467</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x000e1;ndez-Romero</surname><given-names>D</given-names></name><name><surname>V&#x000ed;lchez</surname><given-names>JA</given-names></name><name><surname>Lahoz</surname><given-names>A</given-names></name><name><surname>Romero-Aniorte</surname><given-names>AI</given-names></name><name><surname>Orenes-Pi&#x000f1;ero</surname><given-names>E</given-names></name><name><surname>Caballero</surname><given-names>L</given-names></name><etal>et al</etal></person-group><article-title>High-sensitivity troponin T as a biomarker for the development of
atrial fibrillation after cardiac surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2014</year><volume>45</volume><issue>4</issue><fpage>733</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">24163361</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyse</surname><given-names>DG</given-names></name><name><surname>Waldo</surname><given-names>AL</given-names></name><name><surname>DiMarco</surname><given-names>JP</given-names></name><name><surname>Domanski</surname><given-names>MJ</given-names></name><name><surname>Rosenberg</surname><given-names>Y</given-names></name><name><surname>Schron</surname><given-names>EB</given-names></name><collab>Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
Investigators</collab><etal>et al</etal></person-group><article-title>A comparison of rate control and rhythm control in patients with
atrial fibrillation</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><issue>23</issue><fpage>1825</fpage><lpage>1833</lpage><pub-id pub-id-type="pmid">12466506</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Savino</surname><given-names>JS</given-names></name><name><surname>Friedman</surname><given-names>AS</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Mangano</surname><given-names>DT</given-names></name><etal>et al</etal></person-group><article-title>Atrial fibrillation following coronary artery bypass graft surgery:
predictors.outcomes.and resource utilization MultiCenter Study of Perioperative
Ischemia Research Group</article-title><source>JAMA</source><year>1996</year><volume>276</volume><issue>4</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">8656542</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almassi</surname><given-names>GH</given-names></name><name><surname>Schowalter</surname><given-names>T</given-names></name><name><surname>Nicolosi</surname><given-names>AC</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Moritz</surname><given-names>TE</given-names></name><name><surname>Henderson</surname><given-names>WG</given-names></name><etal>et al</etal></person-group><article-title>Atrial fibrillation after cardiac surgery: a major morbid
event?</article-title><source>Ann Surg</source><year>1997</year><volume>226</volume><issue>4</issue><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">9351718</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuller</surname><given-names>JA</given-names></name><name><surname>Adams</surname><given-names>GG</given-names></name><name><surname>Buxton</surname><given-names>B</given-names></name></person-group><article-title>Atrial fibrillation after coronary artery bypass grafting. Is it a
disorder of the elderly?</article-title><source>J Thorac Cardiovasc Surg</source><year>1989</year><volume>97</volume><issue>6</issue><fpage>821</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">2566713</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>MS</given-names></name><name><surname>Eagle</surname><given-names>KA</given-names></name><name><surname>Buckley</surname><given-names>MJ</given-names></name><name><surname>DeSanctis</surname><given-names>RW</given-names></name></person-group><article-title>Atrial fibrillation following coronary artery bypass
surgery</article-title><source>Prog Cardiovasc Dis</source><year>1989</year><volume>31</volume><issue>5</issue><fpage>367</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">2646657</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Creswell</surname><given-names>LL</given-names></name><name><surname>Schuessler</surname><given-names>RB</given-names></name><name><surname>Rosenbloom</surname><given-names>M</given-names></name><name><surname>Cox</surname><given-names>JL</given-names></name></person-group><article-title>Hazards of postoperative atrial arrhythmias</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>56</volume><issue>3</issue><fpage>539</fpage><lpage>549</lpage><pub-id pub-id-type="pmid">8379728</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Fontes</surname><given-names>ML</given-names></name><name><surname>Tudor</surname><given-names>IC</given-names></name><name><surname>Ramsay</surname><given-names>J</given-names></name><name><surname>Duke</surname><given-names>P</given-names></name><name><surname>Mazer</surname><given-names>CD</given-names></name><collab>Investigators of the Ischemia Research and Education Foundation</collab><collab>Multicenter Study of Perioperative Ischemia Research Group</collab><etal>et al</etal></person-group><article-title>A multicenter risk index for atrial fibrillation after cardiac
surgery</article-title><source>JAMA</source><year>2004</year><volume>291</volume><issue>14</issue><fpage>1720</fpage><lpage>1729</lpage><pub-id pub-id-type="pmid">15082699</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zacharias</surname><given-names>A</given-names></name><name><surname>Schwann</surname><given-names>TA</given-names></name><name><surname>Riordan</surname><given-names>CJ</given-names></name><name><surname>Durham</surname><given-names>SJ</given-names></name><name><surname>Shah</surname><given-names>AS</given-names></name><name><surname>Habib</surname><given-names>RH</given-names></name></person-group><article-title>Obesity and risk of new-onset atrial fibrillation after cardiac
surgery</article-title><source>Circulation</source><year>2005</year><volume>112</volume><issue>21</issue><fpage>3247</fpage><lpage>3255</lpage><pub-id pub-id-type="pmid">16286585</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Echahidi</surname><given-names>N</given-names></name><name><surname>Mohty</surname><given-names>D</given-names></name><name><surname>Pibarot</surname><given-names>P</given-names></name><name><surname>Despr&#x000e9;s</surname><given-names>JP</given-names></name><name><surname>O'Hara</surname><given-names>G</given-names></name><name><surname>Champagne</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Obesity and metabolic syndrome are independent risk factors for atrial
fibrillation after coronary artery bypass graft surgery</article-title><source>Circulation</source><year>2007</year><volume>116</volume><issue>11</issue><supplement>Suppl</supplement><fpage>I213</fpage><lpage>I219</lpage><pub-id pub-id-type="pmid">17846306</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>JL</given-names></name></person-group><article-title>A perspective of postoperative atrial fibrillation in cardiac
operations</article-title><source>Ann Thorac Surg</source><year>1993</year><volume>56</volume><issue>3</issue><fpage>405</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">8379709</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crystal</surname><given-names>E</given-names></name><name><surname>Garfinkle</surname><given-names>MS</given-names></name><name><surname>Connolly</surname><given-names>SS</given-names></name><name><surname>Ginger</surname><given-names>TT</given-names></name><name><surname>Sleik</surname><given-names>K</given-names></name><name><surname>Yusuf</surname><given-names>SS</given-names></name></person-group><article-title>Interventions for preventing post-operative atrial fibrillation in
patients undergoing heart surgery</article-title><source>Cochrane Database Syst Rev</source><year>2004</year><issue>4</issue><elocation-id>CD003611</elocation-id><pub-id pub-id-type="pmid">15495059</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>DC</given-names></name><name><surname>Kilborn</surname><given-names>MJ</given-names></name><name><surname>Keech</surname><given-names>AC</given-names></name></person-group><article-title>Interventions for prevention of post-operative atrial fibrillation and
its complications after cardiac surgery: a meta-analysis</article-title><source>Eur Heart J</source><year>2006</year><volume>27</volume><issue>23</issue><fpage>2846</fpage><lpage>2857</lpage><pub-id pub-id-type="pmid">17015402</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuster</surname><given-names>V</given-names></name><name><surname>Ryd&#x000e9;n</surname><given-names>LE</given-names></name><name><surname>Cannom</surname><given-names>DS</given-names></name><name><surname>Crijns</surname><given-names>HJ</given-names></name><name><surname>Curtis</surname><given-names>AB</given-names></name><name><surname>Ellenbogen</surname><given-names>KA</given-names></name><collab>American College of Cardiology/American Heart Association Task Force on
Practice Guidelines</collab><collab>European Society of Cardiology Committee for Practice Guidelines</collab><collab>European Heart Rhythm Association</collab><collab>Heart Rhythm Society</collab></person-group><article-title>ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial
Fibrillation: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines and the European Society of
Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001
Guidelines for the Management of Patients With Atrial Fibrillation): developed in
collaboration with the European Heart Rhythm Association and the Heart Rhythm
Society</article-title><source>Circulation</source><year>2006</year><volume>114</volume><issue>7</issue><fpage>e257</fpage><lpage>e354</lpage><pub-id pub-id-type="pmid">16908781</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeely</surname><given-names>W</given-names></name><name><surname>Goa</surname><given-names>KL</given-names></name></person-group><article-title>Nebivolol in the management of essential hypertension: a
review</article-title><source>Drugs</source><year>1999</year><volume>57</volume><issue>4</issue><fpage>633</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">10235696</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdil</surname><given-names>N</given-names></name><name><surname>Nisanoglu</surname><given-names>V</given-names></name><name><surname>Eroglu</surname><given-names>T</given-names></name><name><surname>T&#x000fc;ten</surname><given-names>R</given-names></name><name><surname>Cihan</surname><given-names>HB</given-names></name><name><surname>Kutlu</surname><given-names>R</given-names></name><etal>et al</etal></person-group><article-title>Choice of medication for radial artery vasodilation in patients
awaiting coronary artery bypass grafting</article-title><source>Turk Gogus Kalp Dama</source><year>2011</year><volume>19</volume><issue>1</issue><fpage>7</fpage><lpage>11</lpage></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toblli</surname><given-names>JE</given-names></name><name><surname>DiGennaro</surname><given-names>F</given-names></name><name><surname>Giani</surname><given-names>JF</given-names></name><name><surname>Dominici</surname><given-names>FP</given-names></name></person-group><article-title>Nebivolol: : impact on cardiac and endothelial function and clinical
utility</article-title><source>Vasc Health Risk Manag</source><year>2012</year><volume>8</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">22454559</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuncer</surname><given-names>M</given-names></name><name><surname>Fettser</surname><given-names>DV</given-names></name><name><surname>Gunes</surname><given-names>Y</given-names></name><name><surname>Batyraliev</surname><given-names>TA</given-names></name><name><surname>Guntekin</surname><given-names>U</given-names></name><name><surname>Gumrukchuoglu</surname><given-names>KhA</given-names></name><etal>et al</etal></person-group><article-title>Comparison of effects of nebivolol and atenolol on P-wave dispersion
in patients with hypertension</article-title><source>Kardiologiia</source><year>2008</year><volume>48</volume><issue>4</issue><fpage>42</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">18447840</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vandeplassche</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>HR</given-names></name><name><surname>Wouters</surname><given-names>L</given-names></name><name><surname>Flameng</surname><given-names>W</given-names></name><name><surname>Borgers</surname><given-names>M</given-names></name></person-group><article-title>Normothermic ischemic cardiac arrest in the isolated working rabbit
heart: effects of dl-nebivolol and atenolol</article-title><source>Basic Res Cardiol</source><year>1991</year><volume>86</volume><issue>1</issue><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">1673598</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Bortel</surname><given-names>LM</given-names></name><name><surname>van Baak</surname><given-names>MA</given-names></name></person-group><article-title>Exercise tolerance with nebivolol and atenolol</article-title><source>Cardiovasc Drugs Ther</source><year>1992</year><volume>6</volume><issue>3</issue><fpage>239</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">1353367</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galderisi</surname><given-names>M</given-names></name><name><surname>D'Errico</surname><given-names>A</given-names></name></person-group><article-title>Beta-blockers and coronary flow reserve: the importance of a
vasodilatory action</article-title><source>Drugs</source><year>2008</year><volume>68</volume><issue>5</issue><fpage>579</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">18370439</pub-id></element-citation></ref></ref-list></back></article>